Patient satisfaction and acceptability of long-term treatment with quetiapine.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  International journal of psychiatry in clinical practice

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.3109/13651509909024770PMID 24941092
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Seroquel: biochemical profile of a potential atypical antipsychotic

  2005cited by this paper
• Patient satisfaction with, and acceptability of, atypical antipsychotics.

  1999cited by this paper
• Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients

  1997cited by this paper
• Quetiapine ('Seroquel'); an effective and well-tolerated atypical antipsychotic.

  1997cited by this paper
• Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.

  1997cited by this paper
• Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.

  1997cited by this paper
• A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia

  1997cited by this paper
• Impact of newer antipsychotics on outcomes in schizophrenia.

  1997cited by this paper
• Subjective response to neuroleptics in schizophrenia

  1997cited by this paper
• The neurocognitive effects of quetiapine (‘seroquel’, ICI 204, 636)

  1997cited by this paper
• Plasma prolactin in schizophrenia subjects treated with Seroquel (ICI 204,636).

  1996cited by this paper
• Pre-clinical Pharmacology of Atypical Antipsychotic Drugs: A Selective Review

  1996cited by this paper
• New Antipsychotics

  1996cited by this paper
• A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables

  1995cited by this paper
• Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life

  1995cited by this paper
• Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life.

  1995cited by this paper
• Patient Satisfaction in Mental Health Care: Evaluating an Evaluative Method

  1995cited by this paper
• Subjective response to neuroleptics and the quality of life: implications for treatment outcome

  1994cited by this paper
• Patient satisfaction: a valid concept?

  1994cited by this paper
• Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association

  1993cited by this paper
• Subjective response to neuroleptics in schizophrenia.

  1993cited by this paper
• Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures

  1992cited by this paper
• A two-year prospective study of treatment compliance in patients with schizophrenia

  1992cited by this paper
• Causes of Neuroleptic Noncompliance

  1986cited by this paper
• Neuroleptic‐Induced Extrapyramidal Reactions: Classification, Description, and Diagnosis

  1983cited by this paper
• A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity

  1983cited by this paper
• An overview of patient satisfaction with psychiatric treatment.

  1983cited by this paper
• Subjective response to antipsychotic drugs.

  1981cited by this paper
• Tardive dyskinesia: summary of a Task Force Report of the American Psychiatric Association. By the Task Force on Late Neurological Effects of Antipsychotic Drugs.

  1980cited by this paper
• A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia

  1978cited by this paper
• Drug default among schizophrenic patients.

  1975cited by this paper
• Why do schizophrenic patients refuse to take their drugs

  1974cited by this paper
• Why do schizophrenic patients refuse to take their drugs?

  1974cited by this paper

• Investigation of hepatic adverse events due to quetiapine by using the common data model

  2023cites this paper
• Non-interventional epidemiological program for investigating the real-life practice of using quetiapine (Seroquel®) in patients with schizophrenia and bipolar affective disorder (EPIDEMICUS)

  2023cites this paper
• Clinician’s Guide to Psychopharmacology

  2021cites this paper
• Interrelationships among Medication Types and Health Characteristics in Individuals with Bipolar Disorder Receiving Integrated Health Services

  2017cites this paper
• Sex Education Groups in a Psychiatric Day Hospital: Clinical Observations

  2016cites this paper
• Attitude towards second‐generation antipsychotics among patients with schizophrenia and their relatives

  2013cites this paper
• Treatment satisfaction and dissatisfaction in patients with chronic low back pain

  2010cites this paper
• Atlas of Schizophrenia

  2010cites this paper
• Quetiapine demonstrates good tolerability and is associated with improvements in extrapyramidal symptoms in patients with schizophrenia switched from other antipsychotics: results of a naturalistic study

  2007cites this paper
• Wirksamkeit und Verträglichkeit von Quetiapin in der stationären Akutbehandlung schizophrener Psychosen: Eine Anwendungsbeobachtung

  2007cites this paper
• Antipsychotic Medications, Schizophrenia and the Issue of Quality of Life

  2007cites this paper
• Observational cross sectional pilot study of adherence with antipsychotic medication in people with schizophrenia or schizoaffective disorders in prisons

  2007cites this paper
• Rapid dose titration of quetiapine for the treatment of acute schizophrenia and acute mania: a case series

  2006cites this paper
• An Open-Label,Effectiveness Study of Long-Term Quetiapine Treatment

  2005cites this paper
• The development and internal consistency of the Satisfaction with Antipsychotic Medication scale

  2005influential citation
• The employment of people with mental illness

  2005cites this paper
• A survey of patient satisfaction with and subjective experiences of treatment with antipsychotic medication.

  2005cites this paper
• On quality of mental health care: Is Australia getting it wrong?

  2005cites this paper
• Clinical effectiveness in adults with chronic schizophrenia.

  2004cites this paper
• New Antipsychotics, Compliance, Quality of Life, and Subjective Tolerability—Are Patients Better Off?

  2004cites this paper
• Managing acute exacerbations of schizophrenia: focus on quetiapine

  2004cites this paper
• Quetiapine. A review of its use in the management of schizophrenia.

  2004cites this paper
• Impact of Atypical Antipsychotics on Quality of Life in Patients with Schizophrenia

  2004cites this paper
• Clinical effectiveness of new generation antipsychotics in adolescent patients.

  2004cites this paper
• Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence

  2004cites this paper
• The Scope for Psychosocial Treatments for Psychosis

  2003cites this paper
• THE ENCYCLOPEDIA OF VISUAL MEDICINE SERIES

  2003cites this paper
• Evaluating antipsychotic medications: predictors of clinical effectiveness. Report of an expert review panel on efficacy and effectiveness.

  2003cites this paper
• A review of the effect of atypical antipsychotics on weight.

  2003cites this paper
• Differential Effect of Quetiapine on Depressive Symptoms in Patients with Partially Responsive Schizophrenia

  2003cites this paper
• Patient satisfaction after switching from conventional to new atypical antipsychotics in schizophrenia

  2002influential citation
• Quetiapine: a well-tolerated and effective atypical antipsychotic.

  2002cites this paper
• Predictors of noncompliance in patients with schizophrenia.

  2002cites this paper
• Improving Outcome in Schizophrenia: The Potential Importance of EPS and Neuroleptic Dysphoria

  2002cites this paper
• Patients’ Subjective Experiences of Antipsychotics

  2002cites this paper
• II The usefulness of the second-generation antipsychotic medications

  2002cites this paper
• Las implicaciones económico-sanitarias del tratamiento con quetiapina: una auditoría del tratamiento a largo plazo para pacientes con esquizofrenia crónica

  2001cites this paper
• Quetiapine in acute mania: a case report (with a six-month follow-up)

  2001cites this paper
• Quetiapine in acute mania: a case report (with a six-month follow-up).

  2001cites this paper
• Quetiapine: efficacy and tolerability in schizophrenia

  2001cites this paper
• Good tolerability equals good results: the patient's perspective.

  2001cites this paper
• The health economic implications of treatment with quetiapine: an audit of long-term treatment for patients with chronic schizophrenia

  2001cites this paper
• The importance of treatment acceptability to patients

  2000cites this paper
• Principles of Practice from the European Expert Panel on the Contemporary Treatment of Schizophrenia

  2000cites this paper
• The scourge of EPS: have atypical antipsychotics solved the problem?

  2000cites this paper
• Opportunities and challenges presented by the new generation antipsychotics

  2000influential citation
• Quetiapine: a review of its safety in the management of schizophrenia.

  2000cites this paper
• The long-term effect of quetiapine (Seroquel TM ) monotherapy on weight in patients with schizophrenia

  2000cites this paper
• Schizophrenia: diagnosis and continuing treatment of Practice from the European Expert Panel on the Contemporary Treatment of Schizophrenia

  2000cites this paper
• Review of quetiapine and its clinical applications in schizophrenia

  2000cites this paper
• The continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment.

  1999influential citation